January 10, Suzhou Nanomicro Technology Co., Ltd. issued a voluntary disclosure announcement for its 2022 annual results forecast.

Earnings Announcement Period

January 1, 2022 to December 31, 2022.

Earnings Forecast 

1. According to the preliminary estimation of the financial department, it is expected that the annual operating revenue for 2022 will be CNY 690 million to 720 million, which will increase by CNY 24,365.32 million to 27,365.32 million, or 54.59% to 61.31% compared with the same period of the previous year.

2. It is expected to achieve net profit attributable to owners of the parent company of CNY 263 million to CNY 283 million for the year 2022, which will increase by CNY 74,910,300 to CNY 94,910,300, or 39.83% to 50.46% compared with the same period of the previous year.

3. Net profit attributable to owners of the parent company after non-recurring gains and losses for the year 2022 is expected to be CNY188 million to CNY 205 million, representing an increase of CNY 15,841,300 to CNY 32,441,300, or 9.20% to 19.08% compared with the same period of the previous year.

Main reasons for the changes in results for the period

(1) Impact of main business 

In 2022, the Company focused on the established development strategy and the requirements of epidemic prevention and control, gave full play to its core competitiveness in the field of biopharmaceutical separation and purification, such as excellent product performance, highly stable quality, sufficient and reliable production capacity and professional and rapid application technology services, paid attention to the introduction of high-end talents, focused on strengthening the construction of marketing and application technology teams, accelerated product iteration and innovation by focusing on customer needs, and actively responded to the impact of the epidemic and market changes. The company has achieved rapid growth in sales revenue of chromatography packing and chromatography media, chromatography consumables, magnetic beads and other product lines. 

(2) Impact of accounting treatment 

In May 2022, the Company completed the industrial and commercial change registration of the acquisition of part of the equity interest of Suzhou Saipu Instruments Co., Ltd. and the Company held a total equity interest of 76.6664% in Saipu Instruments; in June 2022, Saipu Instruments was included in the scope of consolidated statements as a controlling subsidiary of the Company, and the acquisition of the original long-term equity interest of Saipu Instruments in the Company generated an investment income of CNY 51,542,500 measured at fair value. During the period from June to December 2022, it is expected that the operating revenue of SPECTRUM Instruments will be CNY 84 million and the net profit attributable to the owners of the listed company is expected to be RMB 11 million. 

(3) Effect of share-based payment expenses 

The Company expects to amortize share-based payment expenses of CNY 66.13 million in the current year, which is approximately CNY 56.25 million higher than the share-based payment expenses amortized in the previous year.